Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study

Background Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. Objectives To evaluate the drug survival of interleukin (IL)‐23 or the IL‐17 inhibitors approved for the treatment of moderate‐to‐severe psoriasis in elderly patients (aged ≥65 y...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2024-11, Vol.38 (11), p.2175-2185
Hauptverfasser:	Chiricozzi, Andrea, Coscarella, Giulia, Puig, Luis, Vender, Ron, Yeung, Jensen, Carrascosa, José‐Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charles, Ferreira, Paulo, Bastos, Pedro Mendes, Dauden, Esteban, Leite, Luiz, Valerio, Joana, Alcázar‐Viladomiu, Elena, Vilarrasa, Eva, Llamas‐Velasco, Mar, Alessandri‐Bonetti, Mario, Messina, Francesco, Bruni, Manfredo, Di Brizzi, Eugenia Veronica, Ricceri, Federica, Nidegger, Alessia, Hugo, Jan, Mufti, Asfandyar, Daponte, Athina‐Ioanna, Teixeira, Laetitia, Balato, Anna, Romanelli, Marco, Prignano, Francesca, Gkalpakiotis, Spyridon, Conrad, Curdin, Lazaridou, Elizabeth, Rompoti, Natalia, Stratigos, Alexander J., Nogueira, Miguel, Peris, Ketty, Torres, Tiago
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Factors Aged Antibodies, Monoclonal, Humanized - therapeutic use Dermatologic Agents - therapeutic use Female Humans Interleukin-17 - antagonists & inhibitors Interleukin-23 - antagonists & inhibitors Male Middle Aged Psoriasis - drug therapy Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. Objectives To evaluate the drug survival of interleukin (IL)‐23 or the IL‐17 inhibitors approved for the treatment of moderate‐to‐severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged
ISSN:	0926-9959 1468-3083 1468-3083
DOI:	10.1111/jdv.20143